This type of MLL mutation was originally described in adult de novo AML patients with normal karyotype and has since been demonstrated in both childhood and adult ALL and AML as well as in therapy-related leukemia (112), with an overall incidence of 5–10% (113). This evidence concerns the gene KMT2A and leukemia.